The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 29, 2023
Filed:
Aug. 07, 2018
Wave Life Sciences Ltd., Singapore, SG;
Chandra Vargeese, Schwenksville, PA (US);
Zhong Zhong, Hingham, MA (US);
Naoki Iwamoto, Brighton, MA (US);
Jason Jingxin Zhang, Walpole, MA (US);
Jean-Cosme Dodart, Boston, MA (US);
Yuanjing Liu, Arlington, MA (US);
Pachamuthu Kandasamy, Belmont, MA (US);
Sethumadhavan Divakaramenon, Lexington, MA (US);
Genliang Lu, Winchester, MA (US);
Subramanian Marappan, Acton, MA (US);
WAVE LIFE SCIENCES LTD., Singapore, SG;
Abstract
Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and/or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in treatment of C9orf72-related disorders.